GlobeNewswire: Intra-Cellular Therapies Inc. Contains the last 10 of 278 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T11:40:27ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/19/2848571/0/en/Intra-Cellular-Therapies-Announces-Executive-Appointments-and-Leadership-Changes.html?f=22&fvtc=4&fvtv=21255Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes2024-03-19T12:30:38Z<![CDATA[NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the promotion of Michael Halstead, J.D. to the position of President. Mr. Halstead is currently serving as Executive Vice President and General Counsel. In this newly created leadership role, Mr. Halstead will oversee several functions within the Company including legal, human resources, manufacturing & supply chain, quality, compliance, information technology, and external innovation. He will continue to report to Dr. Sharon Mates, Chairman and Chief Executive Officer.]]>https://www.globenewswire.com/news-release/2024/03/06/2841381/0/en/Intra-Cellular-Therapies-to-Participate-in-Three-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=21255Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences2024-03-06T13:00:20Z<![CDATA[NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate in three upcoming investor conferences:]]>https://www.globenewswire.com/news-release/2024/02/27/2835984/0/en/Intra-Cellular-Therapies-to-Present-at-the-44th-Annual-TD-Cowen-Health-Care-Conference.html?f=22&fvtc=4&fvtv=21255Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference2024-02-27T13:00:35Z<![CDATA[NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024 at 11:10 a.m. ET in Boston, MA.]]>https://www.globenewswire.com/news-release/2024/02/22/2833584/0/en/Intra-Cellular-Therapies-Reports-Fourth-Quarter-And-Full-Year-2023-Financial-Results-And-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=21255Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate Update2024-02-22T12:30:17Z<![CDATA[Full year 2023 total revenues of $464.4 million, compared to $250.3 million in 2022]]>https://www.globenewswire.com/news-release/2024/02/08/2825971/0/en/Intra-Cellular-Therapies-to-Host-Fourth-Quarter-and-Full-Year-2023-Financial-Results-Conference-Call-and-Webcast.html?f=22&fvtc=4&fvtv=21255Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast2024-02-08T13:00:20Z<![CDATA[NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, February 22, 2024, to provide a corporate update and discuss details of the Company's financial results for the quarter and year ended December 31, 2023.]]>https://www.globenewswire.com/news-release/2024/01/02/2802619/0/en/Intra-Cellular-Therapies-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html?f=22&fvtc=4&fvtv=21255Intra-Cellular Therapies to Present at the 42nd Annual J.P. Morgan Healthcare Conference2024-01-02T13:00:20Z<![CDATA[NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 8:15 a.m. PT in San Francisco, CA.]]>https://www.globenewswire.com/news-release/2023/12/05/2790858/0/en/Intra-Cellular-Therapies-Highlights-Data-Presentations-at-the-American-College-of-Neuropsychopharmacology-Annual-Meeting.html?f=22&fvtc=4&fvtv=21255Intra-Cellular Therapies Highlights Data Presentations at the American College of Neuropsychopharmacology Annual Meeting2023-12-05T13:00:07Z<![CDATA[Company presents positive results of a pre-specified patient population in Study 403 examining the effects of CAPLYTA® (lumateperone) in patients experiencing a major depressive episode with anxious distress and mixed features.]]>https://www.globenewswire.com/news-release/2023/11/15/2781002/0/en/Intra-Cellular-Therapies-to-Present-at-the-6th-Annual-Evercore-ISI-HealthCONx-Conference.html?f=22&fvtc=4&fvtv=21255Intra-Cellular Therapies to Present at the 6th Annual Evercore ISI HealthCONx Conference2023-11-15T13:00:49Z<![CDATA[NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023 at 3:25 p.m. ET in Miami, FL.]]>https://www.globenewswire.com/news-release/2023/11/02/2772176/0/en/Intra-Cellular-Therapies-Reports-Third-Quarter-2023-Financial-Results-and-Raises-2023-CAPLYTA-Sales-Guidance.html?f=22&fvtc=4&fvtv=21255Intra-Cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance 2023-11-02T11:30:02Z<![CDATA[Q3 2023 total revenues increased to $126.2 million, compared to $71.9 million in the same period in 2022]]>https://www.globenewswire.com/news-release/2023/10/31/2770078/0/en/Intra-Cellular-Therapies-to-Participate-in-Two-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=21255Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences2023-10-31T12:00:16Z<![CDATA[NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate in two upcoming investor conferences:]]>